Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Equity (2022 - 2025)

Entrada Therapeutics has reported Return on Equity over the past 4 years, most recently at 0.44% for Q4 2025.

  • Quarterly results put Return on Equity at 0.44% for Q4 2025, down 60.0% from a year ago — trailing twelve months through Dec 2025 was 0.44% (down 60.0% YoY), and the annual figure for FY2025 was 0.39%, down 59.0%.
  • Return on Equity for Q4 2025 was 0.44% at Entrada Therapeutics, down from 0.29% in the prior quarter.
  • Over the last five years, Return on Equity for TRDA hit a ceiling of 0.3% in Q2 2024 and a floor of 0.44% in Q4 2025.
  • Median Return on Equity over the past 4 years was 0.1% (2023), compared with a mean of 0.11%.
  • Biggest five-year swings in Return on Equity: surged 68bps in 2024 and later plummeted -60bps in 2025.
  • Entrada Therapeutics' Return on Equity stood at 0.42% in 2022, then surged by 94bps to 0.03% in 2023, then skyrocketed by 668bps to 0.15% in 2024, then plummeted by -388bps to 0.44% in 2025.
  • The last three reported values for Return on Equity were 0.44% (Q4 2025), 0.29% (Q3 2025), and 0.18% (Q2 2025) per Business Quant data.